Evidence map›Paper›PMID 39560894›Full record

SynthesisObesity surgery2024

Metabolic-Associated Fatty Liver Disease and Weight Loss After Bariatric Surgery: A Systematic Review and Meta-Analysis.

Fatima Sabench, Elena Cristina Rusu, Helena Clavero-Mestres, Vicente Arredondo-Prats, Marina Veciana-Molins, Sara Muñiz-Piera, Margarita Vives, Carmen Aguilar, Elia Bartra, Marta París-Sans and 2 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Obesity surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Nano-Enhanced Diets: Advancing Metabolic Dysfunction-Related Steatotic Liver Disease (MASLD) - A Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fatima SabenchHospital Universitari Sant Joan de Reus, Reus, Spain.
Elena Cristina RusuInstitut d'Investigació Sanitària Pere Virgili, Tarragona, Spain.
Helena Clavero-MestresRovira I Virgili University, Tarragona, Spain.
Vicente Arredondo-PratsRovira I Virgili University, Tarragona, Spain.
Marina Veciana-MolinsRovira I Virgili University, Tarragona, Spain.
Sara Muñiz-PieraRovira I Virgili University, Tarragona, Spain.
Margarita VivesHospital Universitari Sant Joan de Reus, Reus, Spain.
Carmen AguilarRovira I Virgili University, Tarragona, Spain.
Elia BartraHospital Universitari Sant Joan de Reus, Reus, Spain.
Marta París-SansHospital Universitari Sant Joan de Reus, Reus, Spain.
Ajla AlibalicHospital Universitari Joan XXIII de Tarragona, Tarragona, Spain.
Maria Teresa Auguet QuintillàRovira I Virgili University, Tarragona, Spain. tauguet.hj23.ics@gencat.cat.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH) are increasingly prevalent in patients undergoing bariatric surgery (BS). Understanding their impact on weight loss outcomes after surgery and highlighting the results of surgical techniques such as Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy (SG) in relation to the presence of MASH are essential for improving patient management and predicting long-term success.

methodsA systematic review and meta-analysis were conducted. We searched the PubMed database; inclusion criteria were BS patients with liver impairment data at surgery and weight loss data at follow-up of 6 months or longer. Meta-analyses were conducted using R's meta package, assessing heterogeneity with the I

resultsOut of 1126 eligible studies, 22 were included in the final systematic review. For the MASLD vs. Normal Liver (NL) comparison, no significant difference in BMI change was found at 12 months, but subgroup analysis indicated a possible publication bias (published data vs data collected). In the MASH vs. non-MASH comparison, high heterogeneity was noted at 12 months, and further stratification by surgical technique revealed that SG patients with MASH experienced lower weight loss, approaching statistical significance.

conclusionsMASLD does not significantly affect short-term weight loss outcomes post-BS, but long-term results show variability. Standardized reporting practices and complete data dissemination are essential for future research to enhance meta-analysis reliability and generalizability.

Indexed as

Bariatric SurgeryNon-alcoholic Fatty Liver DiseaseObesity, MorbidWeight LossGastrectomyGastric BypassHumansTreatment OutcomeBariatric surgeryMASHNAFLD/MASLDRoux-en-Y gastric bypassSleeve gastrectomyWeight loss

Identifiers

PMID39560894
PMCPMC11671570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.